A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there, but was withdrawn from sale after it failed a ...

GSK is betting that Blenrep--a blood-cancer treatment that U.S. drug regulators asked it to pull from the market in 2022--could get a second chance, part of a push by the British pharma giant to ...

of the National Medical Products Administration or NMPA in China has granted Breakthrough Therapy Designation to Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone or ...

Japan's Ministry of Health, Labour and Welfare has also granted Blenrep orphan drug designation, which GSK said "reflects the high unmet medical need and ensures priority NDA review in multiple ...

(RTTNews) - Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma have been accepted for regulatory review in ...

(Alliance News) - GSK PLC on Tuesday said its Blenrep cancer treatment will undergo review in Japan after successful authorisations recently in the UK and Europe. The London-based pharmaceutical ...

Berenberg estimates an around 9% return on R&D investment from its current late-stage pipeline dominated by its multiple myeloma treatment Blenrep and its severe asthma drug depemokimab ...